SLC5A2 and heart failure: A reduced risk of short‐term mortality and cardiovascular events with the use of an SGLT2 inhibitor in patients with diabetes and a high risk of cardiovascular disease has been demonstrated, and an improved prognosis has also been shown in heart failure patients without diabetes who were prescribed an SGLT2 inhibitor.31, 32